
Urban Fritsche
Urban Fritsche is a pharmaceutical analyst at Zürcher Kantonalbank, specializing in the evaluation of biotech and pharmaceutical companies. He provides insights into market dynamics and the potential impacts of drug development on stock performance. In recent news, he commented on the implications of a possible merger between AstraZeneca and Bristol Myers Squibb, highlighting that such a deal could lead to increased competition and market shifts.
Power618
Reach7,645
Country presence
Recent news mentions
Urban Fritsche, a pharmaceutical analyst, discussed the potential advantages for competitors like Roche and Novartis if the merger occurs.
Gerüchte um Megafusion zwischen AstraZeneca und BMS irritieren den MarktNeue Zürcher Zeitung·
Switzerland· 2026-08-03







